Circulating ovarian steroids and endometrial matrix metalloproteinases (MMPs)

Patrick Henriet, Cornet PB, Patricia B. Cornet, Pascale Lemoine, Lemoine P, Christine Galant, Galant C, Christian F. Singer, Singer CF, Courtoy PJ, Pierre J. Courtoy, Eeckhout Y, Yves Eeckhout, Marbaix E, Étienne Marbaix, Etienne Marbaix
Annals of the New York Academy of Sciences · 2002 · vol. 955(1) , pp. 119–138 · doi:10.1111/j.1749-6632.2002.tb02773.x · PMID:11949942 · W1970637166
Review OA: closed CC0 ⤵ 19 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review explores how ovarian steroids regulate endometrial matrix metalloproteinases and their inhibitors, noting progesterone's general inhibitory role but also highlighting local controls like cytokines and sex steroid receptor variations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Recent studies strongly suggest that matrix metalloproteinases (MMPs) play a key role in the initiation of menstrual bleeding in the human endometrium upon the fall of ovarian steroid serum concentrations by inducing the degradation of the extracellular matrix of this mucosa. MMPs are also involved in abnormal endometrial bleeding and have been identified in endometriotic foci. In all cases, they are associated with areas of extracellular matrix breakdown. This paper reviews the literature on the regulation by estradiol and progesterone of the expression and activation of MMPs, and of the expression of their tissue inhibitors (TIMPs), (i) in the endometrium in situ during normal cycle, (ii) during artificial cycles in spayed monkeys, and (iii) in cultures of endometrial explants or purified cells. Whereas progesterone consistently decreases the activity of endometrial MMPs, its effects vary in intensity, duration, and pattern between MMPs as well as among experimental systems. The contribution and limitations of the various investigations are therefore discussed. The focal heterogeneity points to additional local controls of the expression and activation of MMPs in human endometrium, acting beyond the general inhibitory role of progesterone, for example, by cytokines. Focal changes in type or abundance of sex steroid receptors also could be responsible for spatial variation in the expression of MMPs in the endometrium and endometriotic lesions.

My notes (saved in your browser only)

MeSH descriptors

Endometrium Estradiol Matrix Metalloproteinases Ovary Progesterone Animals Cytokines Cytokines Endometrium Endometrium Enzyme Activation Estradiol Estradiol Female Humans In Vitro Techniques Matrix Metalloproteinases Ovary Progesterone Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (67)

Cited by (20)

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:00:24.492322+00:00
unpaywall
last seen: 2026-10-19T06:34:38.229974+00:00
License: CC0 · commercial use OK